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BACKGROUND The strut coverage in OCT is used as a surrogate
marker of chronic stent healing, however less data is available
regarding the acute healing response in the ﬁrst week.
METHODS There were 13 BMS and 15 DES implanted into the coronary
arteries in an overstretch model. OCT follow-up was performed at 1, 3, 7,
14, and 28 days post implantation and assessed strut apposition, coverage
and neoinitmal volume per 1 mm of stent (CAAS intravascular, Pie Medi-
cal). A proteomic approach was used to measure changes in proteins
expression in the arterial neointima over time following implantation of
drug-eluting (DES, Xience Pro, Abbott, USA) and same metallic platform
bare-metal stents (BMS, MLVision, Abbott, USA) compared to balloon an-
gioplasty in porcine coronary arteries.
RESULTS In the early period after implantation a higher neointimal
volume per 1 mm for BMS (0.240.028mm3 vs. 0.250.024mm3;
p¼0.025) without differences between BMS and DES in the stent struts
malapposition (6.842.63% vs. 8.042.35%; p¼0.75) and in stent strut
coverage (45.504.94% vs. 36.734.41%; p¼0.25) was found. At 28
days post implantation the difference in in-stent neoinitmal volume
per 1mm (0.700.13 vs. 0.680.02; p¼0.89), struts coverage
(94.8442.89 vs. 98.9310.51 p¼0.778) and number of malapposed
struts (0.8660.52 vs. 0.4070.40 p¼0.238) were similar for BMS and
DES. Animals were sacriﬁced at each of these time-points and their
coronary arteries were retrieved with subsequent separate analysis of
the vascular media and neointima (for time-point 28). A total of 145
ECM and ECM-associated proteins were identiﬁed by mass spec-
trometry. A comparison of the media versus neointima revealed an
increase of collagens and regulatory proteins, such as small leucine
rich proteins in the media, while basement membrane proteins were
predominantly found in the neointima. Only by day 28, the neointima
in DES compared to BMS showed increased expression of proteins
involved in the regulation of calciﬁcation.
CONCLUSIONS Early healing events in ﬁrst week after stent implan-
tation involve less neointimal volume in DES and initially similarproteomic proﬁles for DES and BMS. After 28 days there are differ-
ences in extracellular matrix-related protens between DES and BMS. It
suggest the high biocompatibility of permanent ﬂuorinated polymer
coated DES in the acute phase after implantation.
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BACKGROUND Late stent failures (late stent thrombosis, late catch-
up, and accelerated neoatherosclerosis) were reported in mono-
therapy drug eluting stents (DES). The beneﬁts of the new “dual”
therapy endothelial-progenitor-cell capturing sirolimus-eluting
COMBO stent (OrbusNeich, FL, US) were analyzed.
METHODS Four longitudinal sequential OCTs in each patient were
obtained in this prospective, single center study; at baseline (for best
stent optimization); at early FUs from 2-5M (4 monthly groups in
1:2:2:1 ratio for % strut coverage); at 9M (for neointima metrics), and at
24M (for neointimal changes). Clinical event adjudication & OCT an-
alyses were performed by CRF core laboratory.
RESULTS 61 patients (33% DM and 74 lesions) received 88 COMBO
stents. All 61 patients completed 9M OCT FU but 17 asymptomatic
cases refused 24M OCT (FU rate 68.3%). Median strut coverage
increased from 77.1, 92.5, 92.7, 94.9, 99.5, to 99.2% from 2M, 3M, 4M,
5M, 9M, to 24M, respectively. No late stent thrombosis was recorded
at 36M (clinical FU rate 98.3%) and MACE rate 3.28%. Regarding late
catch-up, rather, signiﬁcant neointima “regression” was documented
from 9M to 24M; in-stent % neointimal volume (%) 17$8 (12$2-21$2) vs
15$7 (11$2-19$4), p¼0.011. Extra-stent-lumen area (Figure 2) was
recorded in 31$1% (23/74) of lesions during ﬁrst OCT (2 to 5M); this
disappeared signiﬁcantly by 9M, representing rapid vessel healing.
Progressively increase in homogeneous neointima (conversion from
heterogeneous & layered neointima) with reduction in peri-strut-low-
density area was observed (Figure 2), representing neointimal matu-
ration without accelerated neoatherosclerosis.1st OCT Follow-up 2nd OCT FU 3rd OCT FU P-value2 months 3 months 4 months 5 monthsP-value 2 vs
5M 9 months 24 months 9 vs. 24MTotal number of
lesions
analyzedn ¼ 12 n ¼ 24 n ¼ 25 n ¼ 13 NA n ¼ 74 n ¼ 51 NAMedian stent
length
analyzed
(mm)23$5 (21$7-
36$4)23$5 (18$8-
26$6)23$2 (18$8-
24$6)19$6 (19$0-
23$4)0$49 22$9 (18$2-
25$4)22$6 (17$8-
25$0)0$67Total number of
frames
analyzedn ¼ 347 n ¼ 627 n ¼ 642 n ¼ 300 NA n ¼ 1884 n ¼ 1279 NATotal number of
struts
analyzedn ¼ 3430 n ¼ 6360 n ¼ 6505 n ¼ 2946 NA n ¼ 18904 n ¼ 12822 NAStrut coverage percentage as deﬁned by 6 categoriesCovered (DþEþF)
(%)77$1 (67$1-
84$7)92$5 (81$9-
94$3)92$7 (86$8-
95$3)94$9 (89$6-
97$6)0$046 99$5 (97$8-
99$9)99$2 (98$6-
99$8)0$62Uncovered
(AþBþC) (%)
22$9 (15$3-
32$9)7$5 (5$7-18$1) 7$4 (4$7-13$2) 5$1 (2$4-10$5) 0$045 0$5 (0$1-2$2) 0$8 (0$2-1$4) 0$60Strut level and frame (cross-section) level OCT analysesMalapposed struts
(%)0$1 (0$1-0$7) 0$4 (0$3-0$7) 0$5 (0$1-0$9) 0$4 (0$1-0$6) 0$64 0$1 (0$1-0$5) 1$3 (1$3-1$3) NANeointimal
thickness
(mm)0$04 (0$00-
0$06)0$04 (0$03-
0$07)0$04 (0$03-
0$07)0$04 (0$03-
0$08)0$49 0$14 (0$08-
0$21)0$12 (0$07-
0$19)<0$001Neointimal area
(NIA) (mm2)0.56 (0.32-
0.63)0.47 (0.33-
0.59)0.55 (0.35-
0.75)0.61 (0.41-
0.90)0.44 1$34 (1$02-
1$65)1$16 (0$92-
1$52)0.001Neointimal volume
(NIV) (mm3)13$6 (9$2-
15$0)10$2 (6$7-
15$17)13$47 (6$0-
18$57)13$7 (10$0-
17$0)0$95 29$9 (22$1-
43$2)26$2 (19$6-
35$8)0$003Percentage NIV
(%)6$8 (3$3-8$4) 6$0 (4$2-8$0) 6$7 (5$2-7$9) 7$5 (6$3-8$9) 0$41 17$8 (12$2-
21$2)15$7 (11$2-
19$4)0$011
